NEW YORK (GenomeWeb) – Fluidigm said after the close of the market on Tuesday that its revenue for the fourth quarter of 2014 is expected to be approximately $33.4 million.
On average, analysts were expecting Q4 revenues of $33.3 million for the South San Francisco, Calif.-based life science analytical and preparatory systems firm.
Organic revenue for Q4 — excluding revenue attributable to its acquisition of DVS Sciences in January 2014 — is expected to be approximately $25.2 million, which would be a 21 percent increase over the $20.9 million in revenues recorded by the company in Q4 2013.
Meantime, Fluidigm said that total revenue for full-year 2014 is expected to be $116.4 million, while organic revenue, less DVS Sciences' contribution, is expected to be $95.9 million.
Fluidigm projects total revenue of between $142 million and $149 million for full-year 2015. These projections incorporate an estimated negative currency-related impact of 3 percent to 4 percent at the midpoint of the range.
"We achieved strong sequential growth within our CyTOF single-cell proteomics product line both in terms of revenue and bookings," Fluidigm CEO Gajus Worthington said in a statement. "Our full-year results are at the high end of our previously stated guidance, despite a currency headwind in the quarter. As in the third quarter, we realized commercial synergy between single-cell genomics and proteomics at a customer and sales representative level."